Please ensure Javascript is enabled for purposes of website accessibility

Why Amyris Plummeted 26% in March

By Maxx Chatsko - Apr 9, 2016 at 9:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Amyris shares slumped lower last month. Here's what you need to know.

AMRS Chart

AMRS data by YCharts.

What: Shares of engineered biology and next-generation industrial biotech company Amyris (AMRS 17.62%) plummeted 26% in March due to continued pessimism about the ability of operations to demonstrate long-promised growth.

So what: During the month, the company announced full-year 2015 earnings that failed to impress. Last summer, Amyris management guided for GAAP revenue of at least $63 million, but actual revenue failed to break $35 million -- the lowest since the company pivoted operations in 2012.

A major shipment of a high-value fragrance molecule -- one in a portfolio that underpins much of the growth story for the company -- was delayed in the fourth quarter due to downstream processing missteps from a third party. Meanwhile, bulk sales of the company's cosmetic ingredient squalane suffered from major headwinds for most of 2015.

There are signs of hope ranging from continually falling production costs to the formation of new partnerships, from expanded joint ventures to two newly launched consumer product portfolios. But after years of over promising and under delivering from management, investors are right to be frustrated.

Now what: At the end of 2014, I called Amyris my favorite stock to buy for 2015 because the company had achieved something no other next-generation industrial biotech company had: demonstrated ability to reign in large-scale manufacturing expenses. I figured that would translate into improved margins, increased interest in the platform, and multi-year sales growth. Obviously, that hasn't occurred.

While high growth is still a possibility, the slow pace of execution puts Amyris' future in doubt, with more than $55 million in debt payments due in 2016 alone. That will likely result in more dilution and less flexibility to throw capital at real growth projects.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amyris, Inc. Stock Quote
Amyris, Inc.
$2.67 (17.62%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.